NewAmsterdam Pharma Co N.V.
A clinical-stage biopharma developing therapies for metabolic diseases with unmet needs.
NAMS | US
Overview
Corporate Details
- ISIN(s):
- NL00150012K9 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- GOOIMEER 2-35, NARRDEN
Description
NewAmsterdam Pharma Co N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases where currently approved treatments have not been sufficiently successful or well-tolerated. The company's lead product candidate is obicetrapib, an oral, low-dose, once-daily CETP inhibitor. It is being investigated as a therapy to lower low-density lipoprotein cholesterol (LDL-C) as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients. The company aims to address the unmet need for a potent, cost-effective, and convenient LDL-lowering treatment. In addition to its dyslipidemia program, the company also explores treatments for other metabolic disorders.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all NewAmsterdam Pharma Co N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for NewAmsterdam Pharma Co N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NewAmsterdam Pharma Co N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
